ARS Pharmaceuticals, Inc. $SPRY Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 94.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,362 shares of the company’s stock after selling 176,364 shares during the quarter. Pictet Asset Management Holding SA’s holdings in ARS Pharmaceuticals were worth $121,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of SPRY. Royal Bank of Canada boosted its position in shares of ARS Pharmaceuticals by 1,075.3% during the 1st quarter. Royal Bank of Canada now owns 18,547 shares of the company’s stock valued at $234,000 after acquiring an additional 16,969 shares during the last quarter. AQR Capital Management LLC purchased a new stake in ARS Pharmaceuticals in the 1st quarter valued at about $140,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in ARS Pharmaceuticals by 13.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 279,840 shares of the company’s stock valued at $3,520,000 after buying an additional 32,526 shares during the period. JPMorgan Chase & Co. raised its holdings in ARS Pharmaceuticals by 7.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 34,560 shares of the company’s stock valued at $603,000 after buying an additional 2,357 shares during the period. Finally, Legal & General Group Plc raised its holdings in ARS Pharmaceuticals by 55.1% in the 2nd quarter. Legal & General Group Plc now owns 54,825 shares of the company’s stock valued at $957,000 after buying an additional 19,484 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Down 1.6%

Shares of SPRY opened at $8.60 on Tuesday. The firm has a market cap of $853.98 million, a P/E ratio of -4.91 and a beta of 0.93. ARS Pharmaceuticals, Inc. has a 12-month low of $6.66 and a 12-month high of $18.90. The company’s 50-day moving average price is $8.39 and its 200 day moving average price is $9.33. The company has a current ratio of 7.28, a quick ratio of 7.06 and a debt-to-equity ratio of 1.47.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.42). The company had revenue of $28.09 million for the quarter, compared to analyst estimates of $25.58 million. ARS Pharmaceuticals had a negative net margin of 203.25% and a negative return on equity of 100.29%. On average, sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -1.54 earnings per share for the current year.

Wall Street Analyst Weigh In

SPRY has been the topic of several research analyst reports. Weiss Ratings lowered shares of ARS Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Zacks Research upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Northland Securities initiated coverage on shares of ARS Pharmaceuticals in a report on Thursday, April 9th. They issued an “outperform” rating and a $25.00 price objective on the stock. Finally, Leerink Partners set a $26.00 price objective on shares of ARS Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, March 10th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.25.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.